Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Coming Soon – July 2019
The ovarian cancer treatment algorithm is rapidly evolving. For decades, chemotherapy was the standard of care for ovarian cancer; however, treatment is moving toward a targeted approach with the introduction of Roche/Genentech/Chugai’s Avastin and three PARP inhibitors: AstraZeneca /Merck Sharp & Dohme’s Lynparza, Clovis Oncology’s Rubraca, and GlaxoSmithKline/Tesaro’s Zejula. Multiple combination therapies using immune checkpoint inhibitors are in late-phase development for ovarian cancer, and we anticipate that this drug class will significantly change the indication’s treatment paradigm.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
Primary research: More than 20 country-specific interviews with thought-leading medical oncologists supported by survey data collected for this and other DRG research.
Key companies: Roche/Genentech, GlaxoSmithKline/Tesaro, Clovis Oncology, AstraZeneca, AbbVie, Merck KGaA, Pfizer, Bristol-Myers Squibb, Merck & Co., ImmunoGen.
Key drugs: Avastin (bevacizumab), Lynparza (olaparib), Zejula (niraparib), Rubraca (rucaparib), Talzenna (talazoparib), Opdivo (nivolumab), Bavencio (avelumab), Tecentriq (atezolizumab), Imfinzi (durvalumab), Keytruda (pembrolizumab), dostarlimab, mirvetuximab soravtansine, cediranib, ofranergene obadenovec.
Epidemiology: Diagnosed incident cases of epithelial ovarian cancer by stage at diagnosis (I-IIA, IIB-IIC, III, and IV).
Population segments in market forecast: Early-stage first line, advanced-stage first line, second-line platinum-sensitive, second-line platinum-resistant and -refractory, third-line platinum-sensitive, third-line platinum-resistant and -refractory, and fourth and subsequent lines.
Market forecast features: Ten-year, annualized, drug-level sales and patient share of key ovarian cancer therapies through 2027, segmented by brands/generics and epidemiological subpopulations.
Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Already a Client? Log in to access this report.
Carolina do Pazo, is a Business Insights Analyst in the oncology division at Decision Resources Group. Prior to joining DRG, she completed a MSc in Biotechnology, Bioprocessing and Business Management with distinction at the University of Warwick, as a Chevening scholar. She also earned her first-class BSc and BEng in Biotechnology from the Universidad ORT. Ms. do Pazo has worked as a Research Scientist at the Institut Pasteur de Montevideo, analysing the ageing process of yeast cells, and has been part of a project between Indiana University and Universidad ORT that analysed the production of nanohybrids for drug delivery systems applications.
Alison Isherwood, , joined Decision Resources Group in 2008, as an Epidemiologist. Alison holds a in Medical Microbiology, Masters by Research in the Life Sciences and a in Epidemiology all from the University of Edinburgh. Prior to joining Decision Resources Inc., she was working on her in Molecular Virology, specializing on the severe acute respiratory syndrome (SARS) coronavirus, at the University of Reading. In her role at Decision Resources Group, Alison is currently an Epidemiology team lead as well as project managing custom epidemiology work in multiple therapy areas. Alison’s area of specialization at DRG is cancer, particularly breast cancer.